COLL stock forecast
Our latest prediction for Collegium Pharmaceutical, Inc.'s stock price was made on the June 3, 2019 when the stock price was at 11.55$.
In the short term (2weeks), COLL's stock price should outperform the market by 1.20%. During that period the price should oscillate between -6.43% and +12.69%.
In the medium term (3months), COLL's stock price should outperform the market by 2.61%. During that period the price should oscillate between -16.15% and +37.21%.Get email alerts
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
At the moment the company generates 296M USD in revenues.
On its last earning announcement, the company reported a loss of -0.35$ per share.
The book value per share is 2.49$
Three months stock forecastJune 3, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|